Deflazacort

Joshi, Neha S.; Rajeshwari, K

doi:10.4103/0022-3859.58942

Cited by 21 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Caution is required because LP is generally considered to resolve spontaneously, only 15% to 20% of cases have a relapsing and remitting course, and recurrences may occur after corticosteroid withdrawal (22.6% in the present series) . Children are more vulnerable to certain side effects of steroids, particularly affecting growth , although prednisolone for the treatment of children with nephrotic syndrome treated (0.5–0.75 mg/kg/day) for a minimum period of 1 year did not seem to affect their growth rate, and catch‐up growth occurred during reduced‐dose or steroid‐free periods .…”

Section: Discussionmentioning

confidence: 66%

Lichen Planus in Childhood: A Series of 316 Patients

Pandhi

Singal

Bhattacharya

2013

Pediatric Dermatology

View full text Add to dashboard Cite

Lichen planus (LP) is infrequently seen in children and the clinical presentation is often atypical. We conducted a retrospective analysis of clinical features and treatment response in childhood LP to date. The clinical profile and treatment response data of patients younger than 14 years old with LP (entered in a predesigned pro forma study) from January 1997 to June 2011 were analyzed. The treatment was administered according to a predetermined departmental protocol and was comprised of topical steroids with or without oral dapsone or corticosteroids. Patients were evaluated for response, adverse effects, and relapse. The study population consisted of 316 children (166 boys, 150 girls), or 18.7% of the total registered patients in the LP clinic. The mean age was 10.28 years (range 2-14 years). Cutaneous lesions were seen in 96.2%. Involvement of the oral mucosa was detected in 18%, nails in 13.9%, scalp in 8.2%, and genitalia in 4.4%. Classic LP was most prevalent (53.8%), followed by eruptive (16.5%), hypertrophic (8.2%), linear (6.9%), and lichen planopilaris (6.3%). LP pigmentosus, annular, and atrophic variants were encountered infrequently. Topical corticosteroids were the most common treatment used in 69.5% of patients, 28.8% of whom had excellent response at 6 months, although 38.8% failed to follow up. Dapsone was prescribed in 20% and systemic steroids in 9.8% of patients. We report the largest series to date of LP in childhood, with a more varied clinical presentation than in previous series. The course and response to treatment were similar to those in adults.

show abstract

Section: Discussionmentioning

confidence: 66%

Lichen Planus in Childhood: A Series of 316 Patients

Pandhi

Singal

Bhattacharya

2013

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…Deflazacort, an oxazoline derivative of prednisolone with anti-inflammatory and immunosuppressive activity, first became available in 1969. The severity of steroid-induced osteoporosis and growth retardation due to deflazacort is less than that associated with other steroids [55]. Multiple randomized clinical trials appeared to indicate that deflazacort had less severe side effects than conventional GCs, but the dose to achieve and maintain equivalent anti-inflammatory efficacy was usually higher than predicted [56].…”

Section: Discussionmentioning

confidence: 99%

Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis

Kavanaugh

Wells

2014

Rheumatology

View full text Add to dashboard Cite

Glucocorticosteroids (GCs) have been employed extensively for the treatment of rheumatoid arthritis (RA) and other autoimmune and systemic inflammatory disorders. Their use is supported by extensive literature and their utility is reflected in their incorporation into current treatment guidelines for RA and other conditions. Nevertheless, there is still some concern regarding the long-term use of GCs because of their potential for clinically important adverse events, particularly with an extended duration of treatment and the use of high doses. This article systematically reviews the efficacy for radiological and clinical outcomes for low-dose GCs (defined as ≤10 mg/day prednisone equivalent) in the treatment of RA. Results reviewed indicated that low-dose GCs, usually administered in combination with synthetic DMARDs, most often MTX, significantly improve structural outcomes and decrease symptom severity in patients with RA. Safety data indicate that GC-associated adverse events are dose related, but still occur in patients receiving low doses of these agents. Concerns about side effects associated with GCs have prompted the development of new strategies aimed at improving safety without compromising efficacy. These include altering the structure of existing GCs and the development of delayed-release GC formulations so that drug delivery is timed to match greatest symptom severity. Optimal use of low-dose GCs has the potential to improve long-term outcomes for patients with RA.

show abstract

“…[8] The potency ratio of DFZ vs PDN is estimated to be 1.28 (6 mg of DFZ : 5 mg PDN). [9] The use of DFZ in Duchenne Muscular Dystrophy,[1011] Juvenile Idiopathic arthritis (previously, juvenile chronic or rheumatoid arthritis),[12] chronic inflammatory diseases in adults,[13] renal transplantation,[14–16] various hematological disorders (non-Hodgkin's lymphoma, idiopathic thrombocytopenic purpura, etc.…”

Section: Introductionmentioning

confidence: 99%

Deflazacort in comparison to other steroids for nephrotic syndrome

Jat

Khairwa

2012

Indian J Nephrol

View full text Add to dashboard Cite

Patients with nephrotic syndrome require steroids for long time and sometimes repeatedly resulting in various adverse effects. Deflazacort (DFZ) had been described as equally effective and with fewer side effects as compared with other steroids. This review evaluates the literature on efficacy and toxicity of DFZ as compared with other therapies for nephrotic syndrome. A systematic review of Pubmed database and Cochrane Central Register of Controlled Trials with last search date of 20th April 2011. Search terms included “nephrotic AND deflazacort” without any limitations. Randomized control trials comparing DFZ vs placebo or other therapies in subjects with nephrotic syndrome were included. Two authors extracted data independently. Three studies meet inclusion criteria and data were synthesized qualitatively. The limited evidence suggested that DFZ appeared to be equally effective in inducing remission or decreasing proteinuria in patients with nephrotic syndrome. It caused significantly less decrease in bone mineral content (BMC) in spine as compared with prednisolone. The results related to weight change, blood pressure change, Cushingoid symptoms, and urinary calcium excretion were inconsistent between included studies. By reviewing the available limited evidence, DFZ appears to be of similar efficacy for nephrotic patients, but there were inconsistent results regarding side effect profile of DFZ as compared with other steroids except for decrease in BMC where DFZ was better. There is need for larger randomized controlled trials to evaluate effectiveness and adverse effect profile of DFZ as compared with other steroids in nephrotic syndrome.

show abstract

Deflazacort

Cited by 21 publications

References 25 publications

Lichen Planus in Childhood: A Series of 316 Patients

Lichen Planus in Childhood: A Series of 316 Patients

Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis

Deflazacort in comparison to other steroids for nephrotic syndrome

Contact Info

Product

Resources

About